Table 3.

Sensitivity and specificity for emerging but not yet accredited laboratory tests

Classification	Tests	Sensitivity	Specificity	References
Microfluidics, lateral and vertical flow immunoassay	mChip-Ld	84%	92%	[75]
	Lyme IgM and IgG	26%	85%	[70]
	Keul-o-test Borreliose Complete IgM and IgG test	32%	88%
	ReaScan + C6 LYME IgG	83%	91%	[71]
	Multiplexed vertical flow assay (xVFA)	86%	96%	[73]
Luminex	Paramagnetic bead-based multiplex assay and INTELLIFLEX System	94%	97%	[74]
ELISpot and cells-based approaches	iSpot LymeTM	54—84%	54 – 94%	[76, 77]
	QuantiFERON-Lyme	70%	na	[78]
	Spirofind	43%	82%	[77]
	LTT-MELISA	30%	53%
	TCR sequencing	56%	99%	[79]
Biomarkers detection	ReaScan CXCL13 assay	78%	95%	[80, 81]
	RecomBead CXCL13 assay	86 – 100%	91 – 97%
	Quantikine CXCL13 ELISA	88 – 100%	89 – 99%	[81, 82]
	Metabolomics techniques	88%	95%	[83]
Raman Spectroscopy (RS)	SERS and DNA aptamers	91%	96%	[84]
	Raman Spectroscopy	85%	90%	[85]
	Raman Spectroscopy & Chemometrics	83%	91%	[86]
PCR-based approaches	Immuno-PCR	69%	98%	[87]

Na not applicable